Pharmacologically,GalNAc-Apc001 exhibited superior therapeutic efficacy by mitigatingthe suppressive effects of sclerostin on Wnt signaling, upregulatingbone formation markers, and enhancing bone mass in a Col1a2+/G610C osteogenesis imperfecta mousemodel. Here, COL1A2 is linked to osteogenesis imperfecta.